The Administrative Core (Core A) will be directed by Roy Herbst, Principal -Investigator of the Yale SPORE in Lung Cancer (YSILC), and co-directed by Ed Kaftan, with support from the program financial management team. Careful oversight by the Administrative Core will be critical to ensure the success of the Yale SPORE in Lung Cancer. Core A is an extension of existing infrastructure provided by YCC Research Administration to support and facilitate transdisciplinary research efforts. The Administrative Core serves as the central coordination point for all YSILC investigators, with responsibility for monitoring the progress of all projects and cores toward a translational/clinical endpoint. The Core Director and Co-Director along with the YSILC Co-PI (Dr. Chen) will have responsibility for leading the YSILC program, setting translational research priorities, identifying new translational research opportunities from emerging data, monitoring the progress of all projects, cores and developmental projects and determining changes in direction of projects, cores and translational research as needed. Interactions among YSILC investigators will be facilitated by Core A to accelerate the translation of laboratory findings into the proposed and future clinical studies. If required, the Core A Director will manage conflicts among YSILC investigators. As a team, the Core personnel will monitor finances, maintain communications among project and core leaders and coordinate meetings, including the weekly lung cancer translational group seminar series, monthly meetings of the Executive Committee, annual meetings of the Internal/External Advisory boards and an annual YSILC retreat. In addition to these functions, the Core will be the primary interface with the NCI, the Beth Israel Deaconess Medical Cancer Center, other lung cancer SPOREs, Yale Cancer Center and Yale University, and will coordinate outreach efforts, including publications (internal and external), website development, seminars, patient/research advocacy activities, and fundraising programs. Through these administrative activities, Core A will be essential to the organization of the YSILC program, to developing a widespread culture of lung cancer basic/clinical/translational research at Yale and to the efficient achievement of the stated program objectives, with the ultimate goal of a significant clinical impact for patients with lung cancer

Public Health Relevance

The Administration Core (Core A) is essential for leading the Yale SPORE in Lung Cancer (YSILC). The Core will provide scientific, financial and administrative oversight for all YSILC activities and make critical decisions regarding project oversight and management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA196530-01
Application #
8931832
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2015-08-26
Project End
2020-07-31
Budget Start
2015-08-26
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$860,745
Indirect Cost
$785,274
Name
Yale University
Department
Internal Medicine/Medicine
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06510
Wilson, Frederick H; Politi, Katerina (2018) ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discov 8:676-678
Wang, Guangchuan; Chow, Ryan D; Ye, Lupeng et al. (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Anastasiadou, Eleni; Jacob, Leni S; Slack, Frank J (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18:5-18
Bisserier, Malik; Wajapeyee, Narendra (2018) Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood 131:2125-2137
Chow, Ryan D; Chen, Sidi (2018) Cancer CRISPR Screens In Vivo. Trends Cancer 4:349-358
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Goldberg, Sarah B; Narayan, Azeet; Kole, Adam J et al. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res 24:1872-1880
Gilles, Maud-Emmanuelle; Slack, Frank J (2018) Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets 22:929-939
Nagarajan, Maxwell B; Tentori, Augusto M; Zhang, Wen Cai et al. (2018) Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue. Anal Chem 90:10279-10285

Showing the most recent 10 out of 74 publications